Protein Linked to Bladder Cancer Spread Discovered
Researchers identified a protein that helps bladder cancer migrate to the lungs, potentially offering a new target for therapy.
Updated on Oct. 9, 2026 in Cancer
A study published on October 9, 2026, in Cellular & Molecular Immunology identified that the protein IGF2BP2 promotes the spread of bladder cancer to the lungs. This discovery highlights a potential pathway that could be inhibited to restrict metastatic growth in patients with advanced disease.
Why it matters
Elevated expression of IGF2BP2 is linked to more advanced bladder cancer stages and poorer survival outcomes. Identifying this protein as a driver of metastasis offers a target for future therapeutic strategies designed to block cancer progression.
In a preclinical study using lung-tropic bladder cancer sublines, researchers used multiomics analysis to confirm that IGF2BP2 expression increases during the metastatic cascade. Genetic ablation of this protein was shown to restrict metastatic outgrowth in lung lesions.
The players
Cellular & Molecular Immunology
A peer-reviewed scientific journal that publishes research on the intersection of cell biology and the immune system.
The details
The protein IGF2BP2 functions by binding to the 3' region of m⁶A-modified complement C3 mRNA, facilitating its translation. This tumor-derived C3 protein recruits neutrophils to the lungs, where they are remodeled into a pro-metastatic T3-like state that encourages tumor growth. By inhibiting or removing IGF2BP2, the research team found that neutrophil recruitment is disrupted and T-cell proliferative activity in the lungs is enhanced.
Timeline
October 9, 2026: Study published in Cellular & Molecular Immunology.
Health Landscape
This finding builds on the established understanding of the metastatic cascade in bladder cancer by identifying the immune-modulating role of the IGF2BP2 protein. It represents a pivot toward targeting the specific molecular interactions that allow tumors to survive and grow in distant organs.
This research is in the early discovery phase and does not currently change existing diagnostic or treatment protocols. Patients managing advanced bladder cancer should discuss the latest developments in targeted therapies with their oncology team.
The takeaway
The study suggests that IGF2BP2 plays a critical role in helping bladder cancer cells colonize the lungs by manipulating the local immune response. Discussing emerging research and targeted therapy options remains a vital part of ongoing care for those managing advanced bladder cancer stages.
Further reading
For more information on current treatment trends, visit our Cancer section.
Source note: This article includes information reported by Nature.
